There have been few population studies on congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency and none in the UK. Estimates of the carrier frequency vary considerably from as low as one in 1281 to as high as one in 11.2 There has been recent interest in the genetics of the condition with the discovery of the genetic linkage between the HLA locus and CAH,3 leading to the possibility of detecting CAH antenatally and elucidating the genetic basis for the salt-losing and nonsalt-losing forms of the condition. These aspects of CAH were investigated in a study of the disease in Wales.
Methods
All patients with CAH due to 21 This discrepancy suggests that some male cases of CAH had not been detected; this was probably because some male salt-losers had died before the diagnosis had been established.
Gene and carrier frequency calculations. In view of the difference in the number of male and female 622 
Discussion
Numbers of cases. It was expected that not all boys with nonsalt-losing CAH would be detected because in them the clinical presentation in this form of the disease is delayed. There was a surprising difference however, between the numbers of male and female salt-losers. This suggests that some male salt-losing CAH cases had died without an established diagnosis. In the study there were 2 brothers of index patients who had died in early life; in retrospect the circumstances surrounding both deaths suggest a salt-losing crisis due to CAH.
There are two possible approaches to the early diagnosis of CAH and to the prevention of death in salt-losing boys. Firstly, it is now well established that the measurement of plasma 170H-progesterone is a reliable test for the early diagnosis of CAH due to 21-hydroxylase deficiency.6 More widespread use and easy availability of this assay in cases of unexplained vomiting and electrolyte disturbances in newborn boys should reduce the numbers of missed salt-losing CAH cases. In addition, the use of assays of plasma renin activity can be useful in documenting salt depletion before any electrolyte disturbance or clinical sign of salt-wasting occurs.7 Secondly, it may be possible to screen newborn boys. A microfilter paper method for plasma 170H-progesterone has been described8 which could, if necessary, be incorporated in the present newborn screening programme for inborn errors of metabolism. However, this would not be cost effective, as, unlike cases of phenylketonuria, such infants die and do not become long-term financial burdens to the community.
Carrier frequency. The carrier frequency (1/55) calculated for CAH in this study makes this the second most common recognisable recessive gene in Wales. It is less common only than cystic fibrosis and is more common than phenylketonuria which has a carrier frequency of 1/59.9 Our results show that CAH is less common in Wales than in Switzerland,'0 but more common than in the USA.' HLA studies. It is clear from our study and from several others3 [11] [12] Genetic basis for salt-losing and non-salt-losing cases.
In Wales, unlike Switzerland,'L salt-losing cases are more than twice as common as nonsalt-losing ones. The genetic basis for the two forms of the condition is unclear. However, we now know that the HLA linkage applies equally in both forms. The most likely explanation for this is that there are two 
